Popular drugs added to Medicare price negotiation program: What it means for Americans

CMS has selected 15 high‑cost Medicare drugs — including Botox and GLP‑1 Trulicity — for the third round of price negotiations under the Inflation Reduction Act, extending for the first time to drugs administered in doctors’ offices. Negotiations will occur in 2026 with any agreed maximum fair prices taking effect January 2028; manufacturers that refuse to agree face a steep federal excise tax and must comply by Feb. 28, 2026. CMS noted that prices from the prior negotiation cycle would have reduced Medicare’s 2024 net covered drug spending by an estimated $8.5 billion (≈36%), signaling potentially material revenue downside for affected pharma products and prompting industry pushback.

Analysis

Market structure: The IRA-driven CMS list shifts pricing power away from originator branded drugs listed (e.g., LLY's Trulicity, ABBV's Botox, PFE's Xeljanz) and toward payers (UNH, CVS) and beneficiaries; expect margin compression of 10-30% on Medicare-derived sales for listed molecules once CMS sets a 'maximum fair price' in 2026 with implementation in Jan 2028. Equity volatility in affected pharma names should rise 25–50% implied vol vs. sector, while modest Treasury demand could push 10-year yields down 5–15 bps if deficit projections are revised lower.

Risk assessment: Tail risks include successful legal challenges or companies refusing to agree and incurring excise taxes (forcing supply withdrawal or global price reallocation), or conversely CMS setting unexpectedly aggressive MFPs that remove >30% of expected 2028 drug revenue for a listed product. Timeline: immediate sentiment shock (days), guidance/analyst revisions (months, esp. through 2026 earnings), realized cashflow effects concentrated 2026–2028. Hidden deps: rebate mechanics, PBM pass‑throughs and international reference pricing arbitrage can mute or magnify net impact.

Trade implications: Direct plays — short 1–2% position in LLY (Trulicity) and ABBV (Botox) via 12–18 month put spreads (sell 20% OTM, buy 35–45% OTM protection) sized to portfolio risk; go long 2–3% UNH/CVS for payer upside (9–12 month calls or stock). Pair trade: long UNH (2%) / short ABBV (1.5%) to capture payer benefit vs. originator pain. Stage entries now, scale up into volatility around CMS MFP publication and the Feb 28, 2026 compliance cutoff.

Contrarian angles: Consensus underestimates offset levers — companies can shift volumes to commercial channels, accelerate label expansions, or accept lower Medicare price but claw back via rebates or international pricing; if a drug's Medicare share <20% of sales the stock impact will often be muted. Historical analogue: prior IRA-negotiated lists produced headline cuts but smaller EPS hits after company offset actions; watch for legal/delay outcomes that could eliminate near-term downside and create oversold recovery opportunities.

Key Decisions for Investors

• Establish a 2.0% portfolio long in UNH (or 1% UNH + 1% CVS) using 9–12 month call options or stock, target hold through 1H 2027; trim/exit if UNH rises >12% or if CMS guidance shows <5% payer benefit.
• Initiate a 1.0–1.5% notional short via 12–18 month put spread on LLY (long 35–45% OTM put, short 20% OTM put) to express downside from Trulicity inclusion; add up to +0.5% if company guidance cuts EPS >5% tied to Medicare pricing.
• Reduce direct exposure to ABBV and PFE by 30–50% over the next 3 months; if either reports product-specific revenue risk >15% for 2028 vs consensus, increase short sizing to 2% notional each.
• Set an event-driven execution rule: within 48 hours of CMS publishing any 'maximum fair price' proposal for a listed drug, if implied 2028 revenue impact >15% vs consensus, deploy additional 0.5–1.0% shorts on that issuer and hedge with payer longs.
• Allocate 1–2% to cash or short-dated volatility hedges (index put spreads on XLV or long VIX call exposure) to protect against sector-wide repricing shocks between now and Feb 28, 2026.